83-3899-80　Rituximab biosimilar–Research Grade 100ug　CD0-M36-100ug

特徴

• 背景
• B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase （CD45R+, CD117+） and progressively increasing in concentration until maturity.
• CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells.
• It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells.
• The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens.
• It is suspected that it acts as a calcium channel in the cell membrane.
• CD20 / MS4A1 is the target of the monoclonal antibodies （mAb） rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias.
• Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 （CVID5）; also called antibody deficiency due to CD20 defect.
• CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.